<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Business in the Burbs &#187; Cancer</title>
	<atom:link href="http://burbsbiz.lohudblogs.com/category/cancer/feed/" rel="self" type="application/rss+xml" />
	<link>http://burbsbiz.lohudblogs.com</link>
	<description>Movers, shakers and newsmakers</description>
	<lastBuildDate>Tue, 25 Aug 2009 19:13:57 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Par Pharma acquires rights to thin-film drug technology</title>
		<link>http://burbsbiz.lohudblogs.com/2008/06/17/par-pharma-acquires-rights-to-thin-film-drug-technology/</link>
		<comments>http://burbsbiz.lohudblogs.com/2008/06/17/par-pharma-acquires-rights-to-thin-film-drug-technology/#comments</comments>
		<pubDate>Tue, 17 Jun 2008 21:41:01 +0000</pubDate>
		<dc:creator>David Schepp</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Drug development]]></category>
		<category><![CDATA[Drug testing]]></category>
		<category><![CDATA[Under contract]]></category>

		<guid isPermaLink="false">http://burbsbiz.lohudblogs.com/2008/06/17/par-pharma-acquires-rights-to-thin-film-drug-technology/</guid>
		<description><![CDATA[	Strativa Pharmaceuticals, the branded drug unit of Par Pharmaceuticals Cos., which employs some 440 workers in Rockland County, has acquired the U.S. rights to a thin-film formulation of an anti-emetic drug, known as Ondansetron, for use by cancer patients.

	Anti-emetics are drugs the prevent nausea and vomiting, frequent side effects of radiation and chemotherapy. The drug, [...]]]></description>
			<content:encoded><![CDATA[	<p>Strativa Pharmaceuticals, the branded drug unit of Par Pharmaceuticals Cos., which employs some 440 workers in Rockland County, has acquired the U.S. rights to a thin-film formulation of an anti-emetic drug, known as Ondansetron, for use by cancer patients.</p>

	<p>Anti-emetics are drugs the prevent nausea and vomiting, frequent side effects of radiation and chemotherapy. The drug, should it make it to market, would resemble breath strips, postage stamp-sized films that dissolve in the mouth.</p>

	<p>Terms of the deal with Warren, N.J.-based MonoSol Rx, the developer of the thin-film technology, weren&#226;&#8364;&#8482;t disclosed, but milestone payments to MonoSol could reach $23.5 million, the companies said.</p>

	<p>U.S. sales of anti-emetics reached more than $1.6 billion last year, Par said.</p>

	<p>Par, based in Woodcliff Lake, N.J., previously secured rights to Ondansetron for use as an oral spray, currently in development.</p>

	<p>MonoSol said it is moving quickly to trials of the thin-film version with the hope of filing a new drug application with U.S. regulators within a year.</p>


 ]]></content:encoded>
			<wfw:commentRss>http://burbsbiz.lohudblogs.com/2008/06/17/par-pharma-acquires-rights-to-thin-film-drug-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
